NCT02302495 2026-04-07
IFM2012-03
University Hospital, Lille
Phase 2 Completed
Clinical Trials
64 trialsNCT00602641 2026-03-03
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT01208766 2026-01-06
HO95
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Completed
NCT03829371 2025-12-03
STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA
University of Turin, Italy
Phase 4 Active not recruiting
NCT02356159 2025-09-30
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02195479 2025-08-22
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT03412565 2025-04-29
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
Janssen Research & Development, LLC
Phase 2 Completed
NCT01998971 2025-04-25
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Completed
NCT01093196 2024-11-07
Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients
Fondazione EMN Italy Onlus
Phase 3 Completed
NCT00551928 2024-07-22
MPRvsMEL200
Fondazione EMN Italy Onlus
Phase 3 Completed
NCT03217812 2024-04-25
A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
Janssen Research & Development, LLC
Phase 3 Completed
NCT04083898 2024-03-19
Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma
Washington University School of Medicine
Phase 1 Terminated
NCT06212596 2024-01-19
MUKtwelve
University of Leeds
Phase 2 Completed
NCT00734149 2023-11-07
MVP
Duke University
Phase 2 Completed
NCT02188368 2023-11-03
Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients
Oncotherapeutics
Phase 2 Terminated
NCT02294357 2023-11-01
Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
Oncotherapeutics
Phase 2 Terminated
NCT02206425 2023-10-31
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
Oncotherapeutics
Phase 1/2 Completed
NCT00049673 2023-09-13
Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma
Canadian Cancer Trials Group
Phase 3 Completed
NCT01063179 2023-06-29
Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients
Fondazione EMN Italy Onlus
Phase 3 Completed
NCT01160107 2023-06-29
RP_MPR
Fondazione EMN Italy Onlus
Phase 2 Completed
NCT01166113 2023-06-29
PCP
Fondazione EMN Italy Onlus
Phase 1/2 Completed
NCT01054144 2021-10-13
Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00051311 2021-09-09
Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02237261 2020-10-19
BPV
University Hospital Heidelberg
Phase 2 Completed
NCT00002678 2020-04-02
Combination Chemotherapy in Treating Patients With Multiple Myeloma
Canadian Cancer Trials Group
Phase 3 Completed
NCT00006890 2020-04-02
Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Canadian Cancer Trials Group
Phase 2 Completed
NCT02773550 2020-01-18
Velcadito
Basque Health Service
Phase 4 Terminated
NCT00689936 2019-11-20
FIRST
Celgene
Phase 3 Completed
NCT00477750 2019-10-11
Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Mayo Clinic
Phase 1/2 Completed
NCT01818752 2019-08-26
CLARION
Amgen
Phase 3 Completed
NCT00074490 2018-12-31
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01335685 2018-01-23
Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma
Takeda
Phase 1/2 Completed
NCT00006184 2017-10-20
Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02072863 2017-05-02
A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma
Amgen
Phase 1/2 Completed
NCT01237249 2017-01-18
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
PETHEMA Foundation
Phase 2 Completed
NCT00040937 2016-12-08
S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
SWOG Cancer Research Network
Phase 2 Completed
NCT00540644 2016-06-21
Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma
Indiana University
Phase 2 Completed
NCT01376401 2016-05-17
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
PETHEMA Foundation
Phase 2 Completed
NCT00406978 2016-05-10
MPTD
University of Turin, Italy
Phase 1/2 Completed
NCT00961467 2016-05-10
RMPT
Fondazione EMN Italy Onlus
Phase 2 Completed
NCT01352338 2016-02-26
REPEAT
UMC Utrecht
Phase 1/2 Completed
NCT00799539 2015-12-02
A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients
Janssen-Ortho Inc., Canada
No longer available
NCT02474563 2015-06-30
Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma
Janssen Korea, Ltd., Korea
Completed
NCT00002548 2015-03-06
SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma
SWOG Cancer Research Network
Phase 3 Completed
NCT00911859 2014-11-18
A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients
Janssen Research & Development, LLC
Phase 2 Completed
NCT00691704 2014-08-19
Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy
Duke University
Phase 2 Completed
NCT00507416 2014-05-01
UPFRONT
Millennium Pharmaceuticals, Inc.
Phase 3 Completed
NCT00002599 2013-12-19
Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00002653 2013-12-19
Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00014339 2013-12-18
Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Unknown